Tegoprubart (AT-1501) - (BESTOW)

June 22, 2026: Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced new long-term Phase 2 BESTOW and BESTOW extension data for tegoprubart in kidney transplant recipients, presented at the American Transplant Congress (June 20–24, 2026). With a mean follow-up of 21 months, kidney function (eGFR) remained higher with tegoprubart vs tacrolimus at each time point; at month 18, mean eGFR was 74 vs 61 mL/min/1.73 m² (≈12 mL/min/1.73 m² advantage; p<0.05). No biopsy-proven acute rejection (BPAR) events occurred after the first six months in tegoprubart-treated patients, while seven BPAR events (9.4% of tacrolimus-treated patients) were reported after six months in the tacrolimus arm, including two after 12 months. Patient-reported outcomes at 52 weeks favored tegoprubart, with significant improvements on MTSOSD-59R (treatment difference -12.2; p<0.05) and KDQOL-36 Symptoms/Problems (difference 5.7; p<0.05). Safety: CNS/kidney-related adverse events (e.g., headache, falls/balance issues, acute kidney injury) and diarrhea were more frequent with tacrolimus; no graft loss, PML, PTLD, BK/CMV nephropathy/disease, or new malignancies were reported; one death in the tegoprubart arm was not attributed to drug. Following an FDA End-of-Phase 2 meeting, Eledon plans to initiate Phase 3 in late 2026 (primary endpoint: 52-week non-inferiority vs tacrolimus on composite of BPAR, graft loss, and death).